FDA approvals of specialty drugs, 2000-2024. [PDF]
Knox SE +4 more
europepmc +1 more source
QBP1 Peptide as a Potential Anti‐Amyloidogenic Therapy for Type 2 Diabetes: An In Vitro Study
The anti‐amyloidogenic peptide QBP1 effectively halts human islet amyloid polypeptide (hIAPP) aggregation, preventing the formation of toxic β‐structured intermediates. Through a combination of biophysical assays, molecular dynamics, and cell‐based studies, QBP1 is shown to preserve β‐cell viability and metabolic homeostasis, positioning it as a ...
María M. Tejero‐Ojeda +8 more
wiley +1 more source
The Saudi FDA drug evaluation timeline in comparison with international counterparts: a retrospective observational study. [PDF]
Algabbani AM, Hafiz R, AlWon B.
europepmc +1 more source
CDK4/6 inhibition promotes CD8+ T cell expansion through tumor‐macrophage crosstalk by activating HIF‐1α and enhancing MIF‐CD44/CD74 signaling. This reprograms TAMs to boost MHC‐I antigen presentation, and CDK4/6 inhibitor‐trained M1 TAM supernatant therapy synergizes with low‐dose PD‐1 blockade to restore antitumor immunity.
Lin He +17 more
wiley +1 more source
Global Pharmaceutical Regulation: Comparative Frameworks and Operations. [PDF]
Umaru OT +6 more
europepmc +1 more source
To combat BET inhibitor resistance in triple‐negative breast cancer, we developed two single‐cell computational frameworks. FR20 quantifies resistance by integrating ferroptosis‐related gene signatures, while D‐FR20 screens for potential re‐sensitizers.
Haizhou Liu +6 more
wiley +1 more source
The Food and Drug Administration's role in supporting therapeutic development to address unmet needs: the National Academies report and beyond. [PDF]
Dhruva SS +3 more
europepmc +1 more source
Discovery of H2 Receptor Antagonists as Colistin Enhancers by Targeting Acid Stress Response
This study identifies YqgB as a key target for restoring colistin susceptibility in mcr‐positive pathogens under acidic conditions by remodeling phospholipid composition and reducing LPS modification. Deep learning‐based screening reveals H2 receptor antagonists as novel colistin adjuvants. Further investigations indicate that ranitidine and famotidine
Jinju Cai +7 more
wiley +1 more source
Reply : Primary suspect drugs of cataracts in pediatric patients: FDA adverse events reporting database analysis. [PDF]
Khan SM +3 more
europepmc +1 more source
Improved Systemic Immunochemotherapy Employing an Oxaliplatin‐TLR7/8 Agonist Prodrug Strategy
A platinum(IV) prodrug is developed to systemically deliver the TLR7/8 agonist gardiquimod. Tumor‐targeting is mediated by an albumin‐binding maleimide, which limits premature complex activation. Ox‐Gardi‐Mal accumulates specifically in the tumor, where it activates the immune system.
Michael Gutmann +15 more
wiley +1 more source

